A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients (MAESTRO-NAFLD1)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04197479 |
|
Recruitment Status :
Completed
First Posted : December 13, 2019
Last Update Posted : September 5, 2023
|
Sponsor:
Madrigal Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Madrigal Pharmaceuticals, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | January 6, 2023 |
| Actual Study Completion Date : | January 6, 2023 |